ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1737

Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort

Monica Bray1, Andrea Ramirez 1, Eyal Muscal 1 and Marietta De Guzman 2, 1Baylor College of Medicine, Houston, TX, 2Baylor College of Medicine/Texas Children's Hospital, Houston, TX

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Coronary Aneurysm, Kawasaki disease, pediatric rheumatology and cyclophosphamide, systemic vasculitides

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Kawasaki disease is classically thought to be a monophasic disease that primarily targets the coronary arteries. The American Heart Association Kawasaki guidelines note that patient with severe coronary involvement may have peripheral aneurysms but does not specify which patients to image and how to follow peripheral involvement over time.  Hoshino et al followed a cohort of twenty patients with peripheral aneurysms and concluded a diameter greater than 10 millimeters was associated with increased risk of development of stenotic lesions. The risks of additional radiation and sedation to image pediatric patients’ peripheral vessels must be weighed against the benefit of detection peripheral lesions that may cause hemodynamically significant lesions as the patients grow. In this case series, we discuss the presentation and outcome of seven patients found to have peripheral artery aneurysms at a single institution.

Methods: With approval from the Baylor College of Medicine institutional review board, a retrospective review of the medical records of KD patients identified to have peripheral vessel disease was performed. Data including ethnicity, sex, age at diagnosis, total days of fever, day of illness first intravenous immunoglobulin (IVIG) received, coronary aneurysms, peripheral aneurysm characteristics and medications received were abstracted by chart review.

Results: The median age was 9 months, with range of 2 months to 7 years. Most patients described are Hispanic in ethnicity, with one Asian and one African American. Four of the patients described were male and three were female. The median days of fever was 13 days with range of 6 to 34 days. The median day of illness that first IVIG was received was day 10 with range from day 4 to day 34. Six of seven patients had giant coronary aneurysms at some point in the disease course. The peripheral arteries involved were axillary, subclavian, aorta, iliac and femoral. All of the patients received intravenous methylprednisolone in addition to the first IVIG. Three of the seven received a second IVIG, five received infliximab, three received anakinra, and three received cyclophosphamide. Median duration of follow-up was 18 months with range from 2 months to 8 years. Notably, the youngest four of the seven had no coronary aneurysms observed on echo at last follow-up.

Conclusion: Patients described in this cohort had severe disease and often required aggressive multi-modal immunomodulation due to persistent systemic inflammation and extra-coronary involvement. It is reasonable to obtain peripheral imaging in patients that have severe coronary involvement at the second echo or 6-week echo. It is the practice of our center to obtain such imaging when the patients are undergoing cardiac computed tomography. More research is required to understand the frequency of clinically relevant peripheral changes in patients with Kawasaki disease. From this small case series, young patients under 18 months appear to be at increased risk. It is also important to gather information about the normal size of peripheral vessels for very small body sizes. It is possible that this is an under recognized aspect of the disease.

Common iliac artery aneuryms in 3 month old male


KD peripheral aneursym table

Individual characterisitics of patients


Disclosure: M. Bray, None; A. Ramirez, None; E. Muscal, None; M. De Guzman, None.

To cite this abstract in AMA style:

Bray M, Ramirez A, Muscal E, De Guzman M. Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/systemic-vascular-involvement-in-kawasaki-disease-a-single-center-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-vascular-involvement-in-kawasaki-disease-a-single-center-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology